



Dynavax Technologies Corporation  
Investor Relations Department  
2929 Seventh Street  
Berkeley, CA 94710  
United States

[Visit IR website](#)

[Sign-up for Email alerts](#)

**NASDAQ: DVAX**

Last Trade:	9.25
Trade Time:	4:00 PM ET Jul 27, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	3.20 - 17.50
Volume	1,704,898

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jul 28, 2017*

[Dynavax Announces FDA Advisory Committee Vote in Favor of HEPLISAV-B \(TM\)](#)

*Jun 2, 2017*

[Dynavax Presents Updated Data for SD-101 in Combination with KEYTRUDA\(R\) \(pembrolizumab\) Highlighting an ORR in 7 out of 7 Patients Naive to an Anti-PD-1 or Anti-PD-L1 Therapy](#)

*May 19, 2017*

[Dynavax to Present Data on SD-101 in Combination with KEYTRUDA\(R\) at the 2017 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)

*May 8, 2017*

[Dynavax Reports First Quarter 2017 Financial Results](#)

*Apr 3, 2017*

[Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

*Mar 13, 2017*

[Annual Report \(10-K\)](#)

*Jul 10, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 8, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 7, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 8, 2016*

[Quarterly Report \(10-Q\)](#)